Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1987 Nov;70(2):276–282.

Genetic restriction of cytolysis during equid herpesvirus 1 subtype 2 infection.

C G Bridges 1, N Edington 1
PMCID: PMC1542070  PMID: 2827921

Abstract

Six Welsh Mountain pony foals were experimentally infected with a subtype 2 isolate of Equid Herpesvirus 1 (EHV-1) and subsequently examined for T cell mediated cytotoxicity against both subtypes. Cytotoxicity was not observed at 3 or 7 days after primary exposure but virus-specific, and genetically restricted, cytotoxicity of EHV-1-labelled autologous skin fibroblasts could be demonstrated 7 and 21 days after the animals were given a second exposure to live virus. Killing of subtype 2 antigen-labelled targets was more efficient than subtype 1 coated cells. This finding was paralleled by the observation that virus-neutralizing and complement-fixing antibody levels were subtype specific after the primary infection but after secondary exposure were directed against both subtypes. During primary infection the lymphocyte proliferative response to EHV-1 subtype 2 was not evident at 7 days post infection (dpi) but by 18 dpi was present in all animals. The second exposure produced an earlier (3 dpi) and larger proliferative response which was specific to the infecting isolate. The non-specific proliferative response to Concanavalin A mitogen indicated that virus infection induced a state of activation in circulating lymphocytes.

Full text

PDF
276

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen G. P., Bryans J. T. Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections. Prog Vet Microbiol Immunol. 1986;2:78–144. [PubMed] [Google Scholar]
  2. Bridges C. G., Edington N. Innate immunity during Equid herpesvirus 1 (EHV-1) infection. Clin Exp Immunol. 1986 Jul;65(1):172–181. [PMC free article] [PubMed] [Google Scholar]
  3. Burrows R., Goodridge D., Denyer M. S. Trials of an inactivated equid herpesvirus 1 vaccine: challenge with a subtype 1 virus. Vet Rec. 1984 Apr 14;114(15):369–374. doi: 10.1136/vr.114.15.369. [DOI] [PubMed] [Google Scholar]
  4. Campbell T. M., Studdert M. J., Blackney M. H. Immunogenicity of equine herpesvirus type 1 (EHV1) and equine rhinovirus type 1 (ERhV1) following inactivation by betapropiolactone (BPL) and ultraviolet (UV) light. Vet Microbiol. 1982 Dec;7(6):535–544. doi: 10.1016/0378-1135(82)90047-5. [DOI] [PubMed] [Google Scholar]
  5. Chan W. L., Lukig M. L., Liew F. Y. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection. J Exp Med. 1985 Oct 1;162(4):1304–1318. doi: 10.1084/jem.162.4.1304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dutta S. K., Myrup A., Bumgardner M. K. Lymphocyte responses to virus and mitogen in ponies during experimental infection with equine herpesvirus 1. Am J Vet Res. 1980 Dec;41(12):2066–2068. [PubMed] [Google Scholar]
  7. Fitzpatrick D. R., Studdert M. J. Immunologic relationships between equine herpesvirus type 1 (equine abortion virus) and type 4 (equine rhinopneumonitis virus). Am J Vet Res. 1984 Oct;45(10):1947–1952. [PubMed] [Google Scholar]
  8. Gerber J. D., Marron A. E., Bass E. P., Beckenhauer W. H. Effect of age and pregnancy on the antibody and cell-mediated immune responses of horses to equine herpesvirus 1. Can J Comp Med. 1977 Oct;41(4):471–478. [PMC free article] [PubMed] [Google Scholar]
  9. Horohov D. W., Wyckoff J. H., 3rd, Moore R. N., Rouse B. T. Regulation of herpes simplex virus-specific cell-mediated immunity by a specific suppressor factor. J Virol. 1986 May;58(2):331–338. doi: 10.1128/jvi.58.2.331-338.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Iwasaka T., Sheridan J. F., Aurelian L. Immunity to herpes simplex virus type 2: recurrent lesions are associated with the induction of suppressor cells and soluble suppressor factors. Infect Immun. 1983 Dec;42(3):955–964. doi: 10.1128/iai.42.3.955-964.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Liew F. Y. New aspects of vaccine development. Clin Exp Immunol. 1985 Nov;62(2):225–241. [PMC free article] [PubMed] [Google Scholar]
  12. Mumford J. A., Bates J. Trials of an inactivated equid herpesvirus 1 vaccine: challenge with a subtype 2 virus. Vet Rec. 1984 Apr 14;114(15):375–381. doi: 10.1136/vr.114.15.375. [DOI] [PubMed] [Google Scholar]
  13. Nash A. A., Gell P. G. Membrane phenotype of murine effector and suppressor T cells involved in delayed hypersensitivity and protective immunity to herpes simplex virus. Cell Immunol. 1983 Feb 1;75(2):348–355. doi: 10.1016/0008-8749(83)90332-5. [DOI] [PubMed] [Google Scholar]
  14. Nash A. A., Gell P. G., Wildy P. Tolerance and immunity in mice infected with herpes simplex virus: simultaneous induction of protective immunity and tolerance to delayed-type hypersensitivity. Immunology. 1981 May;43(1):153–159. [PMC free article] [PubMed] [Google Scholar]
  15. Patel J. R., Edington N., Mumford J. A. Variation in cellular tropism between isolates of equine herpesvirus-1 in foals. Arch Virol. 1982;74(1):41–51. doi: 10.1007/BF01320781. [DOI] [PubMed] [Google Scholar]
  16. Quinnan G. V., Jr, Kirmani N., Esber E., Saral R., Manischewitz J. F., Rogers J. L., Rook A. H., Santos G. W., Burns W. H. HLA-restricted cytotoxic T lymphocyte and nonthymic cytotoxic lymphocyte responses to cytomegalovirus infection of bone marrow transplant recipients. J Immunol. 1981 May;126(5):2036–2041. [PubMed] [Google Scholar]
  17. Sethi K. K., Omata Y., Schneweis K. E. Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes. J Gen Virol. 1983 Feb;64(Pt 2):443–447. doi: 10.1099/0022-1317-64-2-443. [DOI] [PubMed] [Google Scholar]
  18. Shearer G. M., Schmitt-Verhulst A. M. Major histocompatibility complex restricted cell-mediated immunity. Adv Immunol. 1977;25:55–91. doi: 10.1016/s0065-2776(08)60931-1. [DOI] [PubMed] [Google Scholar]
  19. Thomson G. R., Mumford J. A., Campbell J., Griffiths L., Clapham P. Serological detection of equid herpesvirus 1 infections of the respiratory tract. Equine Vet J. 1976 Apr;8(2):58–65. doi: 10.1111/j.2042-3306.1976.tb03291.x. [DOI] [PubMed] [Google Scholar]
  20. Wainberg M. A., Portnoy J. D., Clecner B., Hubschman S., Lagacé-Simard J., Rabinovitch N., Remer Z., Mendelson J. Viral inhibition of lymphocyte proliferative responsiveness in patients suffering from recurrent lesions caused by herpes simplex virus. J Infect Dis. 1985 Sep;152(3):441–448. doi: 10.1093/infdis/152.3.441. [DOI] [PubMed] [Google Scholar]
  21. Wilks C. R. In vitro cytotoxicity of serum and peripheral blood leukocytes for equine herpesvirus type 1-infected target cells. Am J Vet Res. 1977 Jan;38(1):117–121. [PubMed] [Google Scholar]
  22. Williamson S. A., Parish N., Chambers J. D., Knight R. A. Human immune responses to herpes simplex virus, varicella-zoster and cytomegalovirus in vitro. Immunology. 1986 Mar;57(3):437–442. [PMC free article] [PubMed] [Google Scholar]
  23. Yasukawa M., Zarling J. M. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. I. Lysis restricted by HLA class II MB and DR antigens. J Immunol. 1984 Jul;133(1):422–427. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES